Effects of L-Carnitine Supplementation on Respiratory Distress Syndrome

Phase 4

Withdrawn

• Conditions: Premature Birth
• Interventions: Drug: Dexamethasone; Drug: L-Carnitine 1G/5mL Injection

• Registration Number: NCT03630367
• Lead Sponsor: Assiut University

Brief Summary

The aim of the present study was to investigate the efficacy of L-carnitine therapy on the occurrence and prognosis of respiratory distress syndrome

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-08-04
• Study First Submitted QC: 2018-08-10
• Study First Posted: 2018-08-14
• Study Start: 2018-10-03
• Primary Completion: 2020-09
• Study Completion: 2020-10
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-22
• Last Update Posted: 2021-04-23

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Pregnant women between 30-37 weeks
• singleton pregnancy

Read More

Exclusion Criteria

• congenital malformed fetus
• Extreme premature

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
study group	L-Carnitine 1G/5mL Injection	women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
study group	Dexamethasone	women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
control group	Dexamethasone	women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous

Primary Outcome Measures

Name	Time	Method
the mean difference in the Apgar score after birth	1 minute	Assessment of fetal general condition

Trial Locations

Locations (1)

Ahmed Abbas; 🇪🇬 Assiut, Cairo, Egypt